Schering Aktiengesellschaft

Jutta Riedl

Ralph Lipp

Jorg Elliesen

Johannes Wilhelm Tack

Clemens Gunther

Ulrich Tauber

Henry Laurent

Peter Esperling

Karin Schmidt-Gollwitzer

Georg Rossling

Andreas Sachse

Patrick Franke

J&ouml;rg Elliesen

Clements Gunther

Clemens Guenther

Ulrich Taeuber

Clemens G&uuml;nther

Varying the daily dose of either or both of the estrogen and the progestogen administered for hormone replacement therapy (HRT) is readily and inexpensively accomplished, without the necessity of the physician prescribing a new product each time the daily dose of the estrogen or progestogen is changed, by administering preferably transdermally the estrogen and the progestogen contained in separate extrudable pharmaceutical compositions from a dispenser which contains means, preferably adjustable only by the attending physician or dispensing pharmacist, for varying the volume of either or both of the respective compositions which is dispensed as a single dose from the dispenser in response to a defined digital dispensing manipulation of the dispenser thereby facilitating optimal compliance to a combination of HRT with individually adjusted dosages of the estrogen and progestogen.

Hormone replacement therapy method

The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and salts. The composition is a hydrogel which is suited for the treatment of rosacea, presbyderma, melasma or skin irritations.

Composition with azelaic acid

Hormone replacement therapy method and hormone dispenser

Transdermal therapeutic systems that contain sex steroids and dimethyl

Varying the daily dose of either or both of the estrogen and the progestogen administered for hormone replacement therapy (HRT) is readily and inexpensively accomplished, without the necessity of the physician prescribing a new product each time the daily dose of the estrogen or progestogen is changed, by administering preferably transdermally the estrogen and progestogen contained in separate extrudable pharmaceutical compositions from a dispenser which contains means, preferably adjustable only by the attending physician or dispensing pharmacist, for varying the volume of either or both of the respective compositions which is dispensed as a single dose from the dispenser in response to a defined digital dispensing manipulation of the dispenser.

Agent for transdermal administration that contains gestodene esters

An agent for transdermal administration contains gestodene, optionally in combination with one or more estrogen(s).

Gestodene-containing agent for transdermal administration

Pharmaceutical preparations are provided comprising antiandrogenically effective substances encapsulated in liposomes. These preparations are preferably used for topical treatment of androgen-dependent diseases.

Pharmaceutical preparations

A transdermal therapeutic system is described, which is characterized in that it contains a crystallization inhibitor and optionally penetration enhancer in an active ingredient-containing adhesive matrix.

Transdermal therapeutic systems with crystallization inhibitors

An agent for transdermal administration contains ergoline derivatives optionally in combination with one or more penetration-enhancing agent or agents.

Growing community of inventors

Berlin, Germany

Jutta Riedl